US FDA Approves Novartis’ New Kidney Disease Drug, Fabhalta News US FDA Approves Novartis’ New Kidney Disease Drug, Fabhalta wbstadmin August 8, 2024 US FDA Approves Novartis’ Fabhalta for IgA Nephropathy, Showing 44% Reduction in Urine Protein Levels. Read More Read more about US FDA Approves Novartis’ New Kidney Disease Drug, Fabhalta
